Abstract
PDN-21 (katacalcin), a peptide from the calcitonin (CT) gene, was measured in plasma from healthy persons and patients with medullary thyroid carcinoma (MTC). PDN-21 was detectable (≥ 10 ng/l) in 73% of normal persons (n = 40). In 17 normal persons with undetectable basal plasma levels, PDN-21 became detectable (≥ 10 ng/l) by stimulation with iv pentagastrin in 7 cases. Basal levels were more often detectable in men than in women. In 65 patients with MTC, PDN-21 levels were highly correlated with CT levels as determined by an “in house” RIA (r = 0.99); the mean ratio of CT/PDN-21, on a molar base, was 0.96 ± 0.33 over the entire range. In iv stimulation tests with pentagastrin, PDN-21 and CT showed good parallelism (mean ratio of CT/PDN-21: 1.1 ± 0.62); in MTC patients with normal basal levels, however, peak to basal ratios during iv pentagastrin testing were higher for PDN-21 than for CT, due to the more sensitive PDN-21 assay. In a selective venous catheter study of a patient with MTC, the mean CT/PDN-21 ratio for all samples was 1.04 ± 0.12, but the peak to peripheral levels were higher for PDN-21 (4.1-fold) than for CT (2.8-fold). In conclusion, determination of PDN-21 by RIA is equivalent to determination of CT in diagnosing MTC patients. In few patients, it might be even slightly more sensitive. PDN-21 should be determined in all cases with borderline CT results.
Similar content being viewed by others
References
Hillyard C.J., Myers C, Abeyasekera G., Stevenson J.C., Craig R.K., Maclntyre I. Katacalcin, a new plasma calcium-lowering hormone. Lancet 7: 846, 1983.
Raue F., Boden M., Girgis S., Rix E., Ziegler R. Katacalcin - ein neuer Tumormarker beim C-Zell-Karzinom der Schilddruse. Klin. Wochenschr. 65: 82, 1987.
Maclntyre I., Hillyard C.J., Murphy P.K., Reynolds J.J., Gaines Das R.E., Craig R.K. A second plasma calcium-lowering peptide from the human calcitonin precursor. Nature 300: 460, 1982.
Tatemoto K., Mutt V. Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285: 417, 1980.
Maclntyre I., Hillyard C.J., Murphy P.K., Reynolds J.J., Gaines Das R.E., Craig R.K. A second plasma calcium-lowering peptide from the human calcitonin precursor — a re-evaluation. Nature 308: 84, 1984.
Hurley D.L., Katz H.H., Tiegs R.D., Calvo M.S., Barta J.R., Heath III, H. Cosecretion of calcitonin gene products: studies with a C18-cartridge extraction method for human plasma PDN-21 (Katacalcin). J. Clin. Endocrinol. Metab. 66: 640, 1988.
Ittner J., Dambacher M.A., Born W., Ketelslegers J.M., Buys-Schaert M., Albert P.M., Lambert A.E., Fischer J.A. Diagnostic evaluation of measurements of carboxylterminal flanking peptide (PDN-21) of the human calcitonin gene in serum. J. Clin. Endocrinol. Metab. 61: 1133, 1985.
Takami H., Shikata J., Horie H., Sekine K., Ito K. PDN-21: Possible tumor marker for medullary thyroid carcinoma. J. Surg. Oncol. 44: 205, 1990.
Woloszczuk W., Schuh H., Kovarik J. Determination of circulating monomeric katacalcin and calcitonin: physiological studies in normal subjects. J. Clin. Chem. Clin. Biochem. 24: 451, 1986.
Hunter W.M., Greenwood F.C. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 794: 495, 1962.
Blind E., Schmidt-Gayk H., Armbruster F.P., Stadler A. Measurement of intact human parathyrin by an extracting two-site immunoradiometric assay. Clin. Chem. 33: 1376, 1987.
Raue F., Minne H.W., Ziegler R. Calcitonin. In: Pesce A. Kaplan L. (Eds), Methods in Clinical Chemistry. Mosby, St. Louis, 1987, p. 696.
Motte P., Vauzelle P., Gardet P. Construction and clinical validation of a sensitive and specific assay for serum mature calcitonin using monoclonal anti-peptide antibodies. Clin. Chim. Acta 174: 35, 1988.
Lynch C, Seth R., Bates D.L., Self C.H. Calcitonin determination by a fast and highly sensitive enzyme amplified immunoassay. J. Immunoassay 9: 179, 1988.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blind, E., Raue, R., Klaiber, T. et al. Evaluation of sensitive PDN-21 (Katacalcin) determination as tumor marker in medullary thyroid carcinoma. J Endocrinol Invest 15, 93–98 (1992). https://doi.org/10.1007/BF03348671
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348671